of inherited deficiency of pulmonary surfactant protein B (SP-B), which results in respiratory failure and a severe form of bronchopulmonary dysplasia (BPD) in infants, suggests a key role of this protein in differentiation of type II cells. Surfactant isolated from SP-B deficient patients has high surface tension and type II cell structure and function is abnormal with failure of lamellar body genesis and incomplete processing of SP-C. We have observed that fetal lung epithelial cells express SP-B mRNA, but unless cultured with glucocorticoid, contain little mature protein and few lamellar bodies. Based on these observations, we hypothesize the expression of mature (8 kDa) SP-B protein is a critical event in differentiation of mature type II cells, promoting fusion of multivesicular bodies to form lamellar bodies where processing of SP-C occurs. The objective of this proposal is to investigate regulatory events in processing of precursor SP-B and SP-C and the role of SP-B protein in surfactant metabolism.
Specific Aim 1 will evaluate the developmental pattern for synthesis and processing of SP-B protein in surfactant metabolism.
Specific Aim 1 will evaluate the developmental pattern for synthesis and processing of SP-B and SP-C proteins and formation of lamellar bodies using fetal rat and human lung explants. The protein studies will use western immunoblotting with epitope specific antibodies as well as pulse-chase immunoprecipitation protocols, and lamellar bodies will be studied with membrane marker antibodies using confocal immunofluorescence and immuno electron microscopy. Studies of Aim 2 will examine responses to modifying levels of SP-B gene expression. SP-B mRNA content will be increased and decreased using recombinant adenoviruses with sense or antisense SP-B cDNA under control of the CMV promoter and hormones will be used to accelerate epithelial cell differentiation. The goal of aim 3 is to study surfactant protein gene expression and phospholipid metabolism in lung tissue from infants with lung disease. SP-B deficient, BPD and control tissue will be cultured as explants for analysis of surfactant protein gene transcription rate and mRNA content, protein processing and content, and synthesis of surfactant phospholipids. Surfactant proteins will also be assayed in lung lavage samples from premature infants to determine whether a developmental deficiency of SP-B contributes to occurrence of respiratory distress and BPD.
Aim 4 will determine the effects of recombinant SP-B expression in lung cells from infants with an inherited deficiency of SP-B. Studies will be carried out in lung explants and with tissue maintained as xenografts in immune deficient mice. The studies of this project will define expression and processing of surfactant proteins during development and enhance our understanding of the role of SP-B in type II cell differentiation and function. Results will relate directly to future development of gene therapy for infants with lung disease due to inherited deficiency of SP-B or other causes.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL056401-03
Application #
6110705
Study Section
Project Start
1998-09-01
Project End
1999-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Hamvas, Aaron; Deterding, Robin; Balch, William E et al. (2014) Diffuse lung disease in children: summary of a scientific conference. Pediatr Pulmonol 49:400-9
Merrill, J D; Ballard, P L; Courtney, S E et al. (2011) Pilot trial of late booster doses of surfactant for ventilated premature infants. J Perinatol 31:599-606
Hibbs, Anna Maria; Black, Dennis; Palermo, Lisa et al. (2010) Accounting for multiple births in neonatal and perinatal trials: systematic review and case study. J Pediatr 156:202-8
Walsh, Michele C; Hibbs, Anna Maria; Martin, Camilia R et al. (2010) Two-year neurodevelopmental outcomes of ventilated preterm infants treated with inhaled nitric oxide. J Pediatr 156:556-61.e1
Posencheg, M A; Gow, A J; Truog, W E et al. (2010) Inhaled nitric oxide in premature infants: effect on tracheal aspirate and plasma nitric oxide metabolites. J Perinatol 30:275-80
Albertine, Kurt H; Dahl, Mar Janna; Gonzales, Linda W et al. (2010) Chronic lung disease in preterm lambs: effect of daily vitamin A treatment on alveolarization. Am J Physiol Lung Cell Mol Physiol 299:L59-72
Zupancic, John A F; Hibbs, Anna Maria; Palermo, Lisa et al. (2009) Economic evaluation of inhaled nitric oxide in preterm infants undergoing mechanical ventilation. Pediatrics 124:1325-32
Kolla, Venkatadri; Gonzales, Linda W; Bailey, Nicole A et al. (2009) Carcinoembryonic cell adhesion molecule 6 in human lung: regulated expression of a multifunctional type II cell protein. Am J Physiol Lung Cell Mol Physiol 296:L1019-30
Ballard, Philip L; Truog, William E; Merrill, Jeffrey D et al. (2008) Plasma biomarkers of oxidative stress: relationship to lung disease and inhaled nitric oxide therapy in premature infants. Pediatrics 121:555-61
Davis, Christiana W; Gonzales, Linda W; Ballard, Roberta A et al. (2008) Expression of nitric oxide synthases and endogenous NO metabolism in bronchopulmonary dysplasia. Pediatr Pulmonol 43:703-9

Showing the most recent 10 out of 94 publications